Holen Sie sich die Stockscreener-App
54.99
0.24%
0.165
Schlusskurs vom Vortag:
$54.83
Offen:
$55
24-Stunden-Volumen:
21,797
Relative Volume:
0.03
Marktkapitalisierung:
$2.36B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-18.15
EPS:
-3.03
Netto-Cashflow:
$-24.94M
1W Leistung:
+1.63%
1M Leistung:
+2.25%
6M Leistung:
+24.15%
1J Leistung:
+96.78%
1-Tages-Spanne:
$54.66
$55.97
1-Wochen-Bereich:
$50.69
$55.97
52-Wochen-Spanne:
$26.38
$59.75
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Vergleichen Sie SLNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SLNO | 54.88 | 2.36B | 0 | -38.99M | -24.94M | -3.03 |
| VRTX | 446.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.48 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno Therapeutics Reports Q3 Progress and Financials - TipRanks
PERCEPTIVE ADVISORS LLC Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Perceptive Advisors LLC Increases Stake in Soleno Therapeutics I - GuruFocus.com
Objective long/short (SLNO) Report - Stock Traders Daily
Soleno Therapeutics Announces Oral Presentations featuring - GlobeNewswire
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc - GuruFocus.com
Soleno Therapeutics' SWOT analysis: rare disease stock poised for FDA decision - Investing.com Australia
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation - Yahoo Finance
HC Wainwright Reiterates Buy Rating for Soleno Therapeutics (NASDAQ:SLNO) - MarketBeat
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth - Simply Wall St
Harbor Capital Advisors Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Soleno Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Capnia Inc stock soars to 52-week high, hits $58 mark - Investing.com
(SLNO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Target Price at $69.86 - Defense World
Emerald Advisers LLC Grows Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $73.00 at Oppenheimer - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week High Following Analyst Upgrade - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stake Boosted by Allspring Global Investments Holdings LLC - Defense World
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth By Investing.com - Investing.com South Africa
Soleno Therapeutics shares remain Outperform as analyst lifts price target on updated sales projections - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth - Investing.com India
Oppenheimer Boosts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $73.00 - MarketBeat
Soleno Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
(SLNO) Technical Data - Stock Traders Daily
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. - GlobeNewswire
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors - Barron's
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA - MSN
Prader-Willi Syndrome Market to Drive Growth with Prominent - openPR
Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR - Insider Monkey
Soleno Therapeutics Inc (SLNO)’s stock price in review: A technical analysis - US Post News
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment - Insider Monkey
The Potential Rise in the Price of Soleno Therapeutics Inc (SLNO) following insiders activity - Knox Daily
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 6.4%Time to Buy? - MarketBeat
Insider’s View: Deciphering Soleno Therapeutics Inc (SLNO)’s Financial Health Through Ratios - The Dwinnex
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. - GuruFocus.com
Taking a look at what insiders are doing to gauge the Soleno Therapeutics Inc (SLNO)’s direction - Knox Daily
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Lifted by The Manufacturers Life Insurance Company - MarketBeat
Soleno Therapeutics Inc [SLNO] Revenue clocked in at $0.00 million, up 29.12% YTD: What’s Next? - The DBT News
Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's Why - Yahoo Canada Finance
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
FDA leans away from advisory meeting for Soleno's PWS drug By Investing.com - Investing.com South Africa
Laidlaw maintains buy rating, $75 target on Soleno Therapeutics By Investing.com - Investing.com Australia
Soleno shares set to surge on positive FDA update - Investing.com India
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):